Home
The Department of Biomedicine

News archive for The Department of Biomedicine

The Department of Biomedicine is glad to welcome the research group lead by Thomas Arnesen, who is currently moving into their new offices and laboratories.
Ina Katrine Nitschke Pettersen defends her dissertation “A study of cellular metabolic flexibility under energy stress”
Development of novel anticancer and cardioprotective agents that target prohibitins and the translation initiation factor eIF4a
The Shank family of proteins functions as a molecular scaffold in the neuronal post-synaptic density, enabling numerous protein-protein interactions. Shanks are large multi-domain molecules, and one of the conserved domains is an SH3 domain. Using high-resolution X-ray crystallography, we show that the SH3 domain in the Shank family has lost its canonical ligand-binding site.
The research group around Karl Johan Tronstad at the Department of Biomedicine has been granted 9.5 million to investigate the causes of chronic fatigue syndrome, or myalgic encephalopathy CFS/ME.
PhD-candidate Pugazendhi Murugan Erusappan will defend his thesis: “Molecular Aspects of Integrin α11 Function”
Sarsia Seed recently announced their new seed funds in Bergen consisting of 300 million NOK. Initial investment can be in the biotechnology company Pluvia founded by Prof. Aurora Martinez according to Sarsia officials.
Open for registration, deadline 20th of February.
Interesting meeting in Molecular Imaging in Cologne, Germany, 05-07.04.2017
The molecular processes of myelin maturation are to a large extent still unknown. A coordinated interplay between regulatory and functional molecules must take place for correct timing of myelin membrane apposition and compaction, such that cytoplasmic channels are also formed in a correct way.
PhD-candidate Oscar Aubi Catevilla will defend his thesis: “Discovery of small-molecule activity modulators of bacterial and human phenylalanine hydroxylase”
A new system for confocal and super-resolution imaging avalible at MIC.
The Norwegian Prime Minister Erna Solberg highlighted James Lorens and his company BerGenBio in her New Year's Address as an example of excellent cancer research and source of inspiration

Pages